Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research Institute group designs DNA vaccine that inhibits growth of cancerous tumors

05.11.2002


A group of researchers at The Scripps Research Institute (TSRI) have developed a novel DNA vaccine that helps the body resist the growth of cancerous tumors by choking off the tumors’ blood supply.



"We stimulate the immune system to recognize proliferating blood vessels in the tumor vasculature and to recruit killer T cells to destroy these vessels," explains TSRI Immunology Professor Ralph Reisfeld, Ph.D., who conducted the study with Research Associate Andreas G. Niethammer, M.D., and others. "Deprived of its blood supply, the tumor [eventually dies]."

Niethammer, Reisfeld, and their collaborators describe their successful pre-clinical studies with the vaccine in an article to be published next month in the journal Nature Medicine.


Though not yet tested in humans, their vaccine has the potential to treat many types of cancer, and it may provide a new strategy for the rational design of cancer therapies.

Two Approaches to Treating Cancer

Cancer is not a single disease, but rather over a hundred diseases caused by various sorts of mutations inside various cells in various tissues. Some mutations upregulate genes, increasing the expression of metalloproteinases for instance; others downregulate them, shutting off production of receptor proteins.

After certain mutations occur, a cancer cell grows out of control, dividing over and over and forming a solid tumor. Cancer tumors often damage the tissues where they are located and some can metastasize and migrate through the bloodstream--the malignant carcinoma that claims so many lives every year.

In recent years, some novel approaches to treating cancer have generated interest in scientific circles and society at large.

One of these approaches to is to try to block the process of angiogenesis, the formation of new blood vessels that bring necessary nutrients and oxygen to the hungry tumor cells. Block angiogenesis, the thinking goes, and you can starve a tumor--like drying out a lake by diverting all its tributaries.

The second approach involves attacking the tumor cells directly with a technique known as active immunotherapy. Active immunotherapy involves giving the immune system a push to start killing cancer cells by presenting the so-called killer T cells with tumor-specific antigen. Antigens are markers--proteins on the surface of a cancer cell, for instance--that are used by the immune system to distinguish one cell from another.

Once a killer T cell is presented with the specific antigen, it is stimulated to expand and selectively attack cells that display that antigen. Since cancer cells are originally "self" cells, the trick is to find some antigen that they display, but which normal cells in the body do not. Fortunately, the mutations that cause cancer often cause such antigens to appear on the surface of cancer cells. Sometimes, these antigens are overexpressed on cancer cells, decorating them much more than normal cells, and sometimes the antigens are expressed only on cancer cells. But in any case, when the immune system is stimulated to specifically attack cells with those antigens, the cancer cells can no longer hide behind their "self" facade.

The drawback to immunotherapy is that tumor cells are often very different from one another, confounding attempts to find a single antigen to broadly attack various cancer tumors. Compounding this problem is that even the original tumor can acquire emergent resistance by mutating--as cancer cells often do--and downregulate the target antigens, becoming invisible to the passing killer T cells.

Similarly, anti-angiogenic approaches are complicated by the fact that there are many ways through which a tumor cell can start angiogenesis. Blocking one may simply cause the tumor cells to use another.

But by combining the two approaches, the TSRI team seems to have solved both problems.

Anti-Angiogenic DNA Vaccines--A New Approach

The solution that Niethammer and Reisfeld employed was to target not the tumor cells themselves but the endothelial cells that proliferate to form new blood vessels. Unlike the tumor cells, which readily mutate to resist treatment, the endothelial cells are not prone to mutations and therefore represent a more stationary target.

And targeting the endothelial cells proved effective because these cells are absolutely necessary for tumor growth, since they provide the blood that the tumor cells need to grow.

The DNA vaccine uses an antigen "marker" known as vascular-endothelial growth factor receptor-2 that is upregulated on endothelial cells--particularly those that are undergoing angiogenesis due to nearby cancer tumor growth.

This antigen DNA is inserted into a "targeting vector," the replication-deficient Samonella typhimurium bacteria, which direct the DNA to lymph nodes in the gut--the so-called Peyer’s patches. Once there, the bacteria die and release the bits of DNA, which are taken up by professional antigen-presenting dendritic cells and macrophages. Within these cells, the DNA is translated into protein and then presented to T cells.

Once the T cells see the growth factor receptor, they are activated and will circulate through the bloodstream targeting potential tumor-supporting angiogenic endothelial cells that display it.

"We hope that these studies established a proof of concept that may eventually contribute to the development of novel cancer therapies," says Niethammer.

The article, "A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth" was authored by Andreas G. Niethammer, Rong Xiang, Jurgen C. Becker, Harald Wodrich, Ursula Pertl, Gabriele Karsten, Brian P. Eliceiri, and Ralph A. Reisfeld and appears in the November 4, 2002 online edition of the journal Nature Medicine. The article will appear in print in the December 2002 edition of the same journal.



This work was supported by the National Institutes of Health, the American Heart Association, the Tobacco-Related Disease Research Program Grant, the Department of Defense, EMD Lexigen Research Center, and by fellowships through Deutsche Krebshilfe and Deutsche Forschungsgemeinschaft.


Keith McKeown | EurekAlert!
Further information:
http://www.scripps.edu/

More articles from Health and Medicine:

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

nachricht Direct conversion of non-neuronal cells into nerve cells
03.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Subaru Telescope helps pinpoint origin of ultra-high energy neutrino

16.07.2018 | Physics and Astronomy

Barium ruthenate: A high-yield, easy-to-handle perovskite catalyst for the oxidation of sulfides

16.07.2018 | Life Sciences

New research calculates capacity of North American forests to sequester carbon

16.07.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>